Mks Inc (MKSI) · Oct 19, 2026 · Disposition
$650M divestiture — All-cash $650M; over 18x projected FY2026 Adjusted EBITDA
MKS announced a $650M Ophir Optics sale, adding balance-sheet flexibility while narrowing its exposure to specialty industrial markets.
MKS is riding strong AI-driven demand in semiconductor and advanced packaging equipment, while its Specialty Industrial market has been the softer, more mixed part of the portfolio. Specialty Industrial revenue rose to $313 million in Q2 2026, but the business had declined 4% in 2025 amid broad industrial weakness.
This is a real portfolio shift, not a routine asset sale. MKS has signed a definitive agreement to sell the Ophir Optics business to TTM for $650 million in cash. The move narrows MKS toward its higher-priority semiconductor and electronics-and-packaging exposure, but also removes a defense, security, and industrial optics business from its Specialty Industrial offering.
The price looks meaningful relative to the asset’s stated earnings base, but the filing does not show the full financial trade-off. MKS says the purchase price is more than 18 times projected FY2026 adjusted EBITDA, implying a relatively small business relative to the $650 million headline value. However, the release provides no revenue, GAAP profit, tax impact, transaction costs, or pro forma effect on MKS earnings, and it does not say how much debt will be repaid or where the proceeds will be deployed.
The balance-sheet benefit is plausible, but not yet quantified. MKS has recently emphasized strong growth and operating leverage from semiconductor and advanced-packaging demand, so cash from a non-core divestiture could give management more flexibility around debt or investment. But “strengthen the balance sheet” is management’s stated intention rather than a disclosed debt-reduction target; the financial benefit cannot yet be scored precisely.
The transaction leaves MKS’s core Ophir Instruments franchise intact. The sale excludes the laser-characterization business and the Ophir brand, limiting the risk that MKS is abandoning photonics altogether. 〔0〕
Execution remains a future step, not cash in hand today. Closing is targeted for the second quarter of 2027 and depends on regulatory approvals and other customary conditions. 〔1〕
Bottom line: This advances MKS’s core-focus and balance-sheet story, but the filing gives no details on proceeds deployment or earnings impact. It is strategically meaningful and financially promising, yet genuinely mixed until the transaction closes and the cash is put to work.
Transaction closing and regulatory approvals, Q2 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!